Date: 07-Aug-2019

IONTAS, Teva announce new antibody optimisation agreement

Under the terms of the agreement, IONTAS will initially apply its proprietary technologies to provide Teva with a panel of optimised antibodies against a defined target. Teva will have the option to enter into further optimisation programmes in the future. The agreement also includes options for the screening of biophysical properties suitable for developable antibodies. Teva recently announced an update on its Ajovy (fremanezumab) clinical development for use in episodic cluster headache, after a Phase III study found that the primary endpoint for weekly average number of cluster headache attacks during the four-week treatment period is unlikely to be met.